SAB Biotherapeutics, Inc. revenue breakdown overview

SAB Biotherapeutics, Inc. revenue for the last year amounted to 1.32 M USD, the most of which — 1.32 M USD — came from its highest performing source at the moment, Human Polyclonal Immunotherapeutic Antibodies, the year earlier bringing 2.24 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought SAB Biotherapeutics, Inc. 1.32 M USD, and the year before that — 2.24 M USD.